EAGLE, Idaho, April 21, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its first quarter 2025 financial results on Tuesday, May 6, 2025.
Pennant invites current and prospective investors to tune into a live webcast to be held the following day, Wednesday, May 7, 2025, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time), during which Pennant’s management will discuss its first quarter results.
To listen to the webcast, or to view any financial or other statistical information required by SEC Regulation G, please visit the Investor Relations section of our website at http://investor.pennantgroup.com. The webcast will be recorded and will be available for replay via the website until 5:00 p.m. Mountain Time on May 7, 2026.
About Pennant
The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services through home health and hospice agencies and senior living communities located throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. Each of these businesses is operated by a separate, independent operating subsidiary that has its own management, employees and assets. More information about Pennant is available at www.pennantgroup.com.
Contact
The Pennant Group, Inc.
(208) 506-6100
ir@pennantservices.com
| Last Trade: | US$28.06 |
| Daily Change: | -0.57 -1.99 |
| Daily Volume: | 109,957 |
| Market Cap: | US$963.860M |
May 16, 2025 May 06, 2025 February 27, 2025 February 03, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
